m6A甲基化调节因子在肿瘤耐药中的作用及机制

The Role and Mechanism of m6A Methylation Regulator in Tumor Drug Resistance

化疗是肿瘤的主要治疗方法之一,长期用药容易产生肿瘤耐药,降低药物疗效导致癌症进展及复发,甚至造成患者死亡。目前肿瘤耐药机制尚不明确,因此需要更深入了解肿瘤的耐药机制,尽快攻克肿瘤耐药。近年来N6-甲基腺苷(m6A)成为研究热点,研究发现m6A是最常见的表观遗传RNA修饰之一,并参与肿瘤耐药过程,有望成为治疗肿瘤耐药的新靶点。本文主要对m6A甲基化调节因子在肿瘤耐药中的作用及分子机制进行综述,旨在为研发m6A修饰靶向治疗药物提供理论基础,为临床治疗策略和新型抗肿瘤药物的发展提供参考。

Chemotherapy is one of the main treatment methods for tumors.Long-term use of drugs is prone to tumor drug resistance,reducing drug efficacy,leading to cancer progression and recurrence,and even causing death.At present,the mechanism of tumor drug resistance is not clear,so it is necessary to understand the mechanism of tumor drug resistance more deeply and overcome tumor drug resistance as soon as possible.In recent years,N6-methyladenosine(m6A)has become a research hotspot.It has been found that m6A is one of the most common epigenetic RNA modifications and participates in the process of tumor drug resistance,which is expected to become a new target for the treatment of tumor drug resistance.This article mainly reviews the role and molecular mechanism of m6A methylation regulators in tumor drug resistance,aiming to provide a theoretical basis for the development of m6 A modified targeted therapeutic drugs,and provide a reference for clinical treatment strategies and the development of new anti-tumor drugs.